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Abstract
Background: Women who have inherited mutations in the BRCA1 or BRCA2 genes have substantially elevated
risks of breast and ovarian cancer. Mutation carriers have various options, including extensive and regular
surveillance, chemoprevention and risk-reducing surgery. The aim of this review is to provide an up-to-date analysis
and to subsequently summarise the available literature in relation to risk-reducing strategies, with a keen focus on
prophylactic surgery.
Methods: The literature review is facilitated by Medline and PubMed databases. The cross-referencing of the
obtained articles was used to identify other relevant studies.
Results: Prophylactic surgery (bilateral mastectomy, bilateral salpingo-oophorectomy or a combination of both
procedures) has proved to be the most effective risk-reducing strategy. There are no randomised controlled trials
able to demonstrate the potential benefits or harms of prophylactic surgery; therefore, the evidence has been
derived from retrospective and short follow-up prospective studies, in addition to hypothetical mathematical
models.
Based on the current knowledge, it is reasonable to recommend prophylactic oophorectomy for BRCA1 or BRCA2
mutation carriers when childbearing is completed in order to reduce the risk of developing breast and ovarian
cancer. In addition, women should be offered the options of rigorous breast surveillance, chemoprevention with
anti-oestrogens–especially for carriers of BRCA2–or bilateral prophylactic mastectomy.
Conclusion: The selection of the most appropriate risk-reducing strategy is not a straightforward task. The impact
of risk-reducing strategies on cancer risk, survival, and overall quality of life are the key criteria considered for
decision-making. Notably, various other factors should be taken into consideration when evaluating individual
mutation carriers’ individual circumstances, namely woman’s age, morbidity, type of mutation, and individual
preferences and expectations.
Although prospective randomised controlled trials concerned with examining the various interventions in relation
to the woman’s age and type of mutation are needed, randomisation is extremely difficult and rather deemed
unethical given the current available evidence from retrospective studies.
Background
Breast cancer remains the leading cause of death in
women aged 40-55 years [1]. Sporadic breast cancer
accounts for 70-80% of all cases [2]. It is estimated that
5-10% of all breast cancers and 25%-40% of breast can-
cers affecting women younger than 35 years of age are
attributable to hereditary causes [2]. Furthermore 60%-
70% of hereditary breast cancers seem to arise secondary
to germline mutations in the BRCA1 and BRCA2 genes
[3,4]. Notably, ovarian cancer is a relatively rare disease:
it affects one in eighty women at some point during
their life time [5]. Hereditary or familial ovarian cancer
is linked to many germline mutations, such as PTEN
(Cowden syndrome), TP53 (Li-Fraumeni Syndrome) and
ATM (ataxia-teleangiectatica-mutated gene) [6]. How-
ever, BRCA1 and BRCA2 gene mutations are found to
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ovarian cancer [6].
Histologically, BRCA1-related breast cancers are pre-
dominantly of the basal subtype, with predominant lym-
phocytic infiltration, and are often more aggressive and
associated with negative prognostic factors, as charac-
terised by numerous mitoses, pleomorphic pattern, poor
differentiation and higher proliferation rates [7-11], as
well as a negative oestrogen and progesterone receptors
status [8,10,12]. Moreover, a lack of HER-2 expression
was observed in breast cancer tumours of BRCA1 car-
riers [13]. On the other hand, tumours associated with
BRCA2 mutations are of a luminal subtype, and tend to
be of a positive oestrogen and progesterone receptors-
status; negative HER-2, on the other hand, do not mark-
edly differ from other hereditary or sporadic breast can-
cers [14]. DCIS is found to be equally as prevalent in
patients who carry deleterious BRCA mutations as in
high familial-risk women who are non-carriers, but ulti-
mately occurs at an earlier age. Interestingly, BRCA
mutations were found in a significant portion of women
with DCIS who were presented for a hereditary risk
a s s e s s m e n t[ 1 5 ] .N o t a b l y ,h i g h - g r a d eD C I Si sa l s om o r e
common in BRCA1 mutation carriers than in those
patients without any mutation [16]. Accordingly, it has
been suggested that BRCA1/2-associated breast cancers
progress through the same intermediate steps as spora-
dic breast cancers, and that DCIS should be considered
as a part of the BRCA1/2 tumour spectrum [17].
Clinically, breast cancer is believed to begin at an ear-
lier age in BRCA1 and BRCA2 gene mutation carriers
compared with sporadic cases. The median age of breast
cancer onset ranges from 40-50 years in BRCA1 and
BRCA2 carriers compared with 60-70 years in sporadic
cases [18,19]. Furthermore, breast tumours in BRCA1/2
carriers are more likely to be bilateral and affect the
contra lateral breast at a later stage [8,12,19]. Further-
more, BRCA1/2 mutation carriers also have a higher
rate of pregnancy-associated breast cancer before the
age of 50 [20,21].
Several studies have suggested no significant differ-
ences between BRCA-associated breast cancer and
non-BRCA associated breast cancer in relapse-free,
event-free, and overall survival [22-24]. On the other
hand, other studies indicate that BRCA-associated
breast cancer presents worse survival rates and overall
prognosis [14,25-28]. Inconsistencies in previous stu-
dies may be due to limitations in study design: in par-
ticular, the studies contain small numbers of BRCA
cases. Additionally, due to the onset occurring at an
extremely early age of those patients with BRCA muta-
tions, it was not always possible to obtain controls
which were considered adequately matched for age. In
addition, inconsistencies in previous studies were due
to the examination of both BRCA1 and BRCA2 muta-
tion groups together. Lee et al., for example, recently
conducted a meta-analysis of 11 previously published
articles [29]. The analysis shows that the BRCA1 muta-
tion carriers have worse predicted overall survival rates
(approximately 5 years) than non-carriers (HR = 1.94,
95% CI, 1.45-2.53). Furthermore, long-term overall sur-
vival (10 years or greater) was found to be worse in
BRCA1 mutation carriers compared with non-carriers
(HR = 1.33, 95% CI, 1.12-1.58). However, they indicate
that there has been no significant heterogeneity
observed across the studies.
Moreover, Lee et al. observes that short-term progres-
sion-free survival in BRCA1 carriers was worse than in
non-BRCA carriers (HR = 1.54). Such observations were
not witnessed in long-term progression survival. In addi-
tion, BRCA2 mutation was not observed to affect either
short- or long-term survival rates, which may be attribu-
ted to the different carcinogenic pathways for BRCA1
and BRCA2 [29].
Most ovarian cancers associated with germ line BRCA
mutations are diagnosed at a younger age and are ulti-
mately determined as high-grade and advanced-stage
serous carcinomas [30]. They have surgical and patholo-
gical characteristics similar to those of sporadic cancers.
BRCA mutations do not seem to play a significant role
in the development of mucinous or borderline ovarian
tumours [21]. Moreover, BRCA1 germline mutation car-
riers are not only at risk of ovarian cancer, but also fal-
lopian tube carcinoma and peritoneal papillary serous
carcinoma [31]. Olivier et al. suggest that peritoneal
papillary serous carcinoma risk amongst BRCA2 carriers
is lower than amongst BRCA1 carriers [31]. Further-
more, hereditary ovarian cancer has a distinctly better
clinical outcome with a longer overall survival and
recurrence-free interval after chemotherapy than spora-
dic cancers [21]. Notably, it has been observed that
BRCA-positive Epithelial Ovarian Cancer patients have
better outcomes than non-hereditary epithelial ovarian
cancer patients [32], and advanced-stage hereditary can-
cer patients survive longer than nonhereditary cancer
patients [33].
The identification of BRCA1 and BRCA2 genes in
1994 and 1995 respectively [34,35] has had a great
impact on the understanding and management of spora-
dic and hereditary breast and ovarian cancers. Whilst
the risk of breast and ovarian cancer in the general
population is 10%-13% and 1.7%, respectively, studies
indicate that a woman with mutations in either BRCA1
or BRCA2 carries a lifetime breast cancer risk of 80%
and 20%-60% for developing breast cancer and ovarian
cancer respectively [3,36]. In the case of BRCA1 gene
mutation carriers, the cumulative risk of cancer by the
age of 70 years ranges between 51% and 95% for breast
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Similar trends are also observed in BRCA2 carriers, as
the risk ranges between 33% and 95% for breast cancer,
and between 4% and 47% for ovarian cancer [37].
Women who have an increased risk of breast and
ovarian cancer are advised to consider risk-reducing
strategies; however, such methods vary in their effective-
ness. These strategies include surveillance (breast self-
examination, clinical breast examination, screening
using mammography and breast magnetic resonance
imaging (MRI), trans-vaginal ultrasound scanning and
serum (CA125), chemoprevention and prophylactic sur-
gery (salpingo-oophorectomy and/or mastectomy)
[38,39]. Risk-reducing strategies have been shown to
h a v ea s s o c i a t i o n sw i t hag a i ni nl i f ee x p e c t a n c yi n
BRCA1/2 carriers. Moreover, extended life expectancy
can range from between a few months to a few years,
although this is ultimately dependent on the prophylac-
tic intervention (Table 1).
The aim of this review is to provide an up-to-date
analysis and to subsequently summarise the available lit-
erature in relation to risk-reducing strategies, with a
keen focus on prophylactic surgery.
Methods
MEDLINE and PubMed were used to search for relative
articles. Articles identified using the key words “breast
cancer”, “BRCA1”, “BRCA2”, “ovarian cancer”, “risk
reducing”, “prophylactic”, “mastectomy”, “oophorect-
omy” and “life expectancy”. Cross referencing was per-
formed to identify other articles not identified at the
initial search.
Results
Surveillance
The efficacy of surveillance in BRCA1/2 mutation car-
riers is difficult to determine. Importantly, it has been
suggested that some BRCA1/2 carriers will not develop
cancer during their lifetime [40], although the identifica-
tion of such individuals is currently impossible. The
concept of surveillance is based on early detection of
cancer rather than cancer prevention. It is suggested
that women at a high risk of developing breast cancer
should perform a monthly breast self-examination, and
also undergo bi-annual clinical examination [41,42] and
annual digital mammography. Owing to the fact that the
sensitivity of mammography is significantly reduced in
Table 1 Life expectancy gains from cancer prevention strategies for BRCA1/2 positive women
Author and year Mutation type Type of prophylactic intervention
vs. surveillance
Life expectancy gain
(year)
Sonnenberg
et al 1993
BRCA 1/2 Tamoxifen for 5 years 1.6 to 2.2
Schrag
et al 1997
BRCA1/2 Bilateral Mastectomy
Bilateral oophorectomy
2.9 to 5.3
0.3 to 1.7
Grann
et al 1998
BRCA1/2 Bilateral oophorectomy
Bilateral mastectomy
Bilateral mastectomy and oophorectomy
0.4 to 2.6
2.8 to 3.4
3.3 to 6.0
Grann
et al 2000
BRCA1/2 Bilateral oophorectomy
Bilateral mastectomy
Bilateral oophorectomy and mastectomy
Chemoprevention with tamoxifen
Chemoprevention with raloxifene
0.9 ( 95% CI: 0.4-1.2)
3.4 (95% CI: 2.7-3.7)
4.3 (95% CI: 3.6-4.6 )
1.6 (95% CI: 1.0-2.1)
2.2 (95% CI: 1.3-2.8 )
Schrag
et al 2000
BRCA1/2 Tamoxifen for 5 years
Bilateral oophorectomy
Contra-lateral mastectomy
0.4 to 1.3
0.2 to 1.8
0.6 to 2.1
van Roosmalen
et al 2002
BRCA1/2 Bilateral mastectomy and oophorectomy
Breast screening and bilateral oophorectomy
Bilateral mastectomy with ovarian screening
High risk: 11.7. Medium risk 6.6
High risk: 9.5. Medium risk 5.3
High risk: 4.9. Medium risk 4.4
Armstrong
et al 2004
BRCA1/2 Bilateral oophorectomy
Bilateral mastectomy and prophylactic oophorectomy
3.34 to 4.65
5.49 to 7.63
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rapid development of breast cancer in BRCA1/2 muta-
tions, the use of alternative and more sensitive imaging
modalities, such as MRI at shorter intervals, has been
recommended [42-44]. However, the malignant lesions
in BRCA mutation carriers frequently have morphologi-
cal characteristics which are commonly seen in benign
lesions, such as a rounded shape or sharp margins. With
this in mind, MRI has the ability to evaluate the
enhancement pattern and kinetics, and hence enables
the detection of characteristics suggestive of a malig-
nancy [45]. The use of MRI in addition to digital mam-
mography for surveillance in BRCA mutation carriers is
considered to be essential in such women–even if their
breast density is low [46]. Undoubtedly, surveillance is
the least invasive option; however, such a method is
associated with various negative consequences, such as
increased anxiety, false reassurance, and unnecessary
biopsies [47,48]. Although MRI is an effective surveil-
lance modality in BRCA mutation carriers–especially in
younger women–a significant proportion of women are
still found to have node positive breast cancer at the
time of diagnosis [49]. Furthermore, whilst regular sur-
veillance in women at an increased familial risk of breast
cancer is associated with a good clinical outcome if they
carry BRCA2 mutations or no detectable mutation, the
outcome in carriers of BRCA1 mutations is significantly
worse, even in the instance that their tumours are diag-
nosed at an apparently early stage [27]. The impact of
regular breast screening in this context on overall survi-
val ultimately remains unclear, and further research is
required in order to evaluate the effect of different
breast-screening strategies according to the mutation
type, type and frequency of screening modality, and age.
Importantly, annual ovarian surveillance–conducted by
pelvic examination, trans-vaginal ultrasound scanning
and serum CA125 measurement–in women at increased
familial risk of ovarian cancer is found to be ineffective
in detecting tumours at a sufficiently early stage, which
substantially influences survival in BRCA1/2 mutation
carriers [50-52]. Serum proteomics technology is cur-
rently being evaluated in the context of ovarian cancer
detection and seems to be promising.
Chemoprevention
It is well recognised that oestrogen plays an essential
role in mammary carcinogenesis by exerting a carcino-
genic effect (through metabolites) on cellular DNA and
thereby promoting the growth of ER positive breast can-
cer [53]. Therefore, chemo-prevention strategies aim to
target the oestrogen receptor signalling pathway or oes-
trogen synthesis. Selective oestrogen receptor modula-
tors (SERMs) have been suggested as chemo-
preventative agents in BRCA mutation carriers. In a
subgroup analysis of the National Surgical Adjuvant
Breast and Bowel Project (NSABP-P1) trial [54], Tamox-
ifen was found to reduce the incidence of breast cancer
in healthy BRCA2 mutation carriers but not in BRCA1
carriers when started at the age 35 years or older [55].
These findings are not surprising given the fact that
BRCA2-related breast cancers are largely ER-positive
tumours, whilst BRCA1-related breast cancers are pre-
dominantly ER-negative [14,56,57]. Furthermore, in
BRCA1 or BRCA2 carriers with breast cancer, Tamoxi-
fen use was associated with the prevention of secondary
and contra lateral breast cancer [58,59].
Prophylaxis with SERMs was estimated to prolong
survival by 1.6 to 2.2 years in BRCA gene mutation car-
riers [60]. The ablation of the endometrial lining can be
considered in BRCA mutation carriers who opt for che-
moprevention with Tamoxifen in order to reduce the
risk of endometrial tumours.
Targeting oestrogen synthesis is considered to be an
alternative to SERMs as a chemo-preventative risk-redu-
cing strategy in high-risk women. Aromatase inhibitors
(AIs) have been shown to be superior to Tamoxifen in
the treatment of ER-positive breast cancer and the pre-
vention of contralateral breast cancer in postmenopausal
women with fewer side effects. It is likely that AIs will
have a prophylactic role to play in BRCA gene carriers
who opt to have prophylactic oophorectomy (PO) and
breast surveillance. However, this potential role requires
further evaluation through prospective controlled trials,
with the inclusion of quality of life issues and skeletal
complications as secondary endpoints.
Based on the knowledge that the risk of ovarian can-
cer and mortality is reduced by 50% and 80% respec-
tively in long-term users of oral contraceptive pills
(OCPs) [61,62], OCPs are considered as potential pre-
ventative measures for women at high risk of developing
ovarian cancer. The use of OCPs was associated with
significant ovarian cancer risk reduction in a case con-
trol study when used for a period of 6 or more years by
BRCA1/2 carriers [63]. However further research is
required in order to assess the chemo-preventative role
of OCP amongst high-risk subjects. Furthermore, their
use is known to be associated with an increased risk of
breast cancer [64]; hence, their use should be considered
in carefully selected candidates.
The non-specific action of existing DNA damage
reagents poses a problem regarding chemoprevention in
BRCA women. Such agents have been found to cause a
similar extent of damage in both BRCA1 mutant and
wild-type cells. The recent discovery that PARP-1 inhi-
bitors kill BRCA1/2 deficient cells with a high level of
specificity subsequently opens up a potential therapy
which looks very hopeful for BRCA1 cancer patients.
A number of studies have illustrated that BRCA1/2
Salhab et al. BMC Women?’?s Health 2010, 10:28
http://www.biomedcentral.com/1472-6874/10/28
Page 4 of 10pre-cancerous cells are very sensitive to PARP inhibi-
tion, whilst cancer cells exhibit different responses to
PARP inhibition under a variety of different conditions.
Furthermore, it has been suggested that these differ-
ences in PARP sensitivity can be attributed to distinct
phases in BRCA associated tumorigenesis. Work con-
ducted by De Soto & Deng [65] demonstrates that, dur-
ing the early stages of tumorigenesis, there is a clear
sensitivity of BRCA mutant cells to PARP inhibition.
This has led to the inference that BRCA-deficient cells
in this early pre-cancerous state receive a permissive
mutation which is sensitive to PARP-1 inhibitors. Such
agents may prove effective in reducing breast cancer
risk amongst BRCA1 and 2 carriers.
Prophylactic Surgery
Risk-reducing surgery in BRCA1/2 gene mutation car-
riers includes prophylactic bilateral salpingo-oophorect-
omy (PBSO) and/or prophylactic bilateral mastectomy
( P B M ) .T h ea i mo fs u r g e r yi st or e d u c et h er i s ko fc a n -
cer development and to reduce mortality.
Notably, extensive counselling should be offered to all
women who consider prophylactic surgery, including a
detailed explanation of the cancer risk, complications
associated with surgery, aesthetic outcome, quality of
life issues, and potential life expectancy gain. The deci-
sion to proceed with prophylactic surgery is largely
patient-driven depending on whether the patient feels
comfortable living with the estimated risk and how she
values the psychosexual function of the breast and ovar-
ies. It is observed that many women who undergo
BRCA testing use these results to make clinical deci-
sions; those who choose risk-reducing surgeries typically
do so within months of receiving BRCA-positive results.
Predictors of risk-reducing surgery uptake include age
below 60 years, prior breast cancer, and utilisation of
another risk-reducing surgery.
Since the establishment of the link between breast and
ovarian cancers and BRCA1/2 genes mutations, in addi-
tion to the increasing availability of genetic testing,
research groups were faced with many questions con-
cerning the efficacy and usefulness of risk-reducing sur-
gery. Earlier studies have more keenly focused on
decisions concerning whether or when to undergo pro-
phylactic surgery. The magnitude of the potential benefit
fundamentally depends on the risk of cancer associated
with specific mutations, the prognosis of the tumours in
carriers of the mutations, and the extent to which relief
of anxiety could result from surgical prophylaxis. These
benefits were to be weighed against an array of potential
costs, including surgical complications and the potential
impacts of mastectomy or oophorectomy on a woman’s
self-image, as well as on their sexual and reproductive
function [66].
Prophylactic bilateral mastectomy (PBM)
There are no randomised controlled trials which have
previously examined the potential impacts of PBM on
survival; therefore, evidence has been derived from ret-
rospective and short follow-up prospective studies in
addition to hypothetical mathematical models with vari-
able estimates.
Earlier studies have utilised the Markov model [60],
which was developed with the objective to determine
the survival benefits in BRCA1/2 carriers who undergo
different types of prophylactic surgery. In studies per-
formed by Grann et al., it was concluded that a 30-year-
old BRCA1/2 positive woman could prolong her survival
by 0.9 years (95% probability interval, 0.4-1.2 years) by
having bilateral oophorectomy, 3.4 years (2.7-3.7 years)
by having bilateral mastectomy, and 4.3 years (3.6-4.6
years) by having both procedures compared with sur-
veillance alone. Chemoprevention with Tamoxifen and
raloxifene was estimated to increase survival by 1.6
years (1.0-2.1 years) and 2.2 years (1.3-2.8 years), respec-
tively. These findings suggest that prophylactic surgery
is associated with substantial survival benefits [67,68].
Other authors show that, compared with breast and
ovarian screening, the average gain in life expectancy for
30-year-old carriers in the high- and medium-risk cate-
gories was 11.7 and 6.6 years respectively for combined
prophylactic mastectomy and oophorectomy, 9.5 and 5.3
years respectively for breast-screening and prophylactic
oophorectomy, and 4.9 and 4.4 years respectively for
prophylactic mastectomy with ovarian screening. This
indicates that combined prophylactic mastectomy and
oophorectomy is the most effective strategy for prolong-
ing life [69]. Furthermore, PO seems to be superior to
BPM in terms of prolonging survival. Similar findings
were reported by Schrag et al. [70]; however, the
authors suggest that gains in life expectancy decline
with age at the time of prophylactic surgery, and are
minimal for 60-year-old women. Also, amongst 30-year-
old women, oophorectomy may be delayed by 10 years
with little loss of life expectancy.
Furthermore, in the case of carriers of BRCA1/2
mutations who subsequently developed breast cancer, it
was found that, with the use of the Markov model and
depending on the assumed penetrance of the BRCA
mutation, probabilities associated with developing contra
lateral breast cancer and ovarian cancer, dying from
these cancers, dying from primary breast cancer, and
the reduction in cancer incidence and mortality due to
prophylactic surgeries and compared with surveillance
alone, 30-year-old early-stage breast cancer patients with
BRCA mutations showed a gain in life expectancy of
approximately 0.4 to 1.3 years from Tamoxifen therapy,
0.2 to 1.8 years from PO, and 0.6 to 2.1 years from
prophylactic contralateral mastectomy (PCM). The
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women with low-penetrance mutations (assumed contra
lateral breast cancer risk of 24% and ovarian cancer risk
of 6%) and greatest for those with high-penetrance
mutations (assumed contra lateral breast cancer risk of
65% and ovarian cancer risk of 40%). Notably, older age
and poorer prognosis from primary breast cancer
further attenuate such gains [71]. Undoubtedly, esti-
mates of life expectancy gain may help women and their
physicians consider the uncertainties, risks, and advan-
tages of such interventions, and may accordingly lead to
more informed choices concerning cancer prevention
strategies [71].
In recent years, a few cohort and case control studies
have considered the effectiveness of prophylactic sur-
gery. However, it is of great importance to mention that
they differ in quality, with some having significant meth-
odological flaws–mainly owing to selection bias and ret-
rospective study design.
Prophylactic bilateral mastectomy reduces the risk of
breast cancer in BRCA mutation carriers by 85%-100%
[72-74]. In a report published by Rebbeck et al., 483
women with BRCA1/2 mutations were studied. After a
mean follow-up of 6.4 years, breast cancer was diag-
nosed in two (1.9%) of 105 women who had bilateral
prophylactic mastectomy, and in 184 (48.7%) of 378
matched controls who did not have the procedure.
The group therefore subsequently concludes that BPM
reduces the risk of breast cancer in women with
BRCA1/2 mutations by approximately 90% [74].
Furthermore, in a prospective study of 139 women
with BRCA1 or BRCA2 mutations, after a mean fol-
low-up of 3 years, breast cancer developed in 8 of 63
women who had elected surveillance, but in none of
the 76 BRCA mutations carriers who had undergone
prophylactic surgery [73]. Similarly, a report on an
extended series with a longer follow-up of women with
BRCA1/2 mutation having undergone PBM at the Rot-
terdam Family Cancer Clinic found that no primary
breast cancer occurred after PBM after a median fol-
low-up of 4.5 years, with one woman presenting meta-
static breast cancer almost four years after her PBM
where no primary was found [75].
It is accepted that no surgical technique for prophy-
lactic mastectomy removes all breast epithelium; simple
mastectomy removes approximately 95%-99% of breast
glandular tissue; however, it causes a significant defor-
mity, changes in body image and sexuality, as well as
adverse effects on the psychosocial status of the affected
woman, but not quality of life [76]. Moreover, it has
been observed that most women opting for prophylactic
mastectomy experienced significantly higher distress
levels than mutation carriers who opted for surveillance
as well as non-mutation carriers. This difference in
levels of distress was found to be highest during pre-
and post-test stages, and had almost disappeared during
the one-year follow-up. Moreover, mutation carriers
opting for prophylactic mastectomy are more often in
their thirties, more often have young children, and also
have a greater awareness of the genetic nature of cancer
in the family than those opting for regular surveillance.
Interestingly, their distress levels seem to significantly
decrease 6 months or longer following surgery, possibly
due to the significant risk reduction of developing breast
cancer [77]. Furthermore, those undergoing mastectomy
with delayed reconstruction report a lower impact on
their self-esteem and sexual life versus those who only
had the mastectomy [78].
Skin sparing mastectomy and immediate breast recon-
struction (SSM & IMR) has been proved to be oncologi-
cally safe, and is associated with high satisfaction rate
and low morbidity [79,80]. More recently, there has been
increasing interest in offering BRCA1/2 carriers SSM and
IBR, either by using an autologous flap, implant or both.
On the other hand, SSM and IBR have many aesthetic
advantages [81], and so it is fundamental to recognise
that 5%-10% of breast tissue can be left in the subcuta-
neous flaps. This residual breast tissue may be a focus for
breast cancer development in high-risk women with
BRCA mutations; therefore, SSM or nipple-sparing mas-
tectomy in risk-reducing surgery setting is feasible in
most patients at an increased risk; however, it should be
the subject of further prospective evaluations in order to
ascertain its long-term oncological safety [82].
Prophylactic bilateral salpingo-oophorectomy (PBSO)
Since breast tumours are largely oestrogen-driven, it
has been suggested that the hormonal blockade by
oophorectomy inhibits the development of breast
tumours [83]. Importantly, prophylactic oophorectomy
has the advantage of preventing ovarian cancer as well
as breast cancer. Prophylactic salpingo-oophorectomy,
and the sectioning of both tubes and ovaries, is recom-
mended in order to ensure occult carcinomas are not
missed. Furthermore, since BRCA mutation carriers
develop fallopian tube carcinoma and peritoneal papil-
lary serous carcinoma, PBSO and sectioning both
t u b e sa n do v a r i e si st h e r e f o r er e c o m m e n d e di no r d e r
to ensure occult carcinomas are not missed [31]. The
demonstrated efficacy of oophorectomy in the case of
BRCA mutation carriers is interesting, simply because
most BRCA1-related breast tumours are negative for
oestrogen receptors [9-11]. This observation can be
attributed to the carcinogenic effect of oestrogen meta-
bolites-DNA adducts [84].
In a large, retrospective analysis of 551 BRCA carriers,
BSO was found to have reduced the risk of ovarian can-
cer by 96% and breast cancer by 53% at a mean follow-
up of 9 years [85]. Similar findings were observed in a
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follow-up of 2 years, the incidence of ovarian or perito-
neal cancer and breast cancer was significantly greater
amongst those women who selected surveillance than
amongst those who chose to undergo PBSO [86]. In a
multicentre prospective study, Kauff et al.f o u n dt h a t ,
during a 3-year follow-up, BPSO was associated with
85% reduction in BRCA1-associated gynaecologic cancer
risk and 72% reduction in BRCA2-associated breast can-
cer risk. Although protection against BRCA1-associated
breast cancer and BRCA2-associated gynaecologic can-
cer was suggested, neither effect reached statistical sig-
nificance. The authors postulate that the protection
conferred by PBSO against breast and gynaecologic can-
cers may differ between the carriers of BRCA1 and
BRCA2 mutations [87].
Although several studies demonstrate that PBSO
decreased the risk of both breast and ovarian cancers in
BRCA1/2 mutation carriers [85-94], these studies were
nevertheless heterogeneous and used different designs:
whilst some were retrospective case control studies,
others used a prospective cohort design. Even amongst
prospective studies, the inclusion criteria and the defini-
tions of follow-up times differed. In some studies, only
unaffected mutation-positive women were included and
followed up; whilst in others–particularly when examin-
ing ovarian cancer risk–women with breast cancer were
included. Such differences in study design can introduce
biases (such as survival bias), and can consequently have
an impact on risk-reduction estimates.
Recently, Rebbeck et al. carried out a meta-analysis of
ten studies which investigated breast or gynaecologic
cancer outcomes in BRCA1/2 mutation carriers who
had undergone PBSO. The authors subsequently con-
cluded that PBSO was associated with a statistically sig-
nificant reduction in breast cancer risk amongst
BRCA1/2 mutation carriers. Similar risk reductions were
observed in BRCA1 mutation carriers and in BRCA2
mutation carriers. Furthermore, PBSO was associated
with a statistically significant reduction in the risk of
BRCA1/2-associated ovarian or fallopian tube cancer;
however, data were deemed insufficient to obtain sepa-
rate estimates for ovarian or fallopian tube cancer risk
reduction. Moreover, PBSO was strongly associated with
reductions in the risk of breast, ovarian, and fallopian
tube cancers, and should provide guidance to women in
planning cancer risk-reduction strategies [95].
Furthermore, in a prospective study with a short-term
follow-up, PBSO was associated with a 90% reduction in
breast cancer-specific mortality, a 95% reduction in
gynaecologic cancer-specific mortality, and a 76% reduc-
tion in overall mortality [89]. Such data demonstrate the
utility of BSO in this population of patients given
the fact that the procedure can be performed
laparoscopically with minimal invasiveness, high efficacy,
and low morbidity [96]. Chemoprevention with anti-
oestrogens–especially in BRCA2 carriers–and breast
surveillance can be added to PBSO in order to enhance
its effective prophylactic role with a limited impact on
quality of life.
Limitations
This review paper provides an up-to-date analysis of our
understanding of the advantages of risk-reducing strate-
gies in BRCA carriers. Although the article summarises
the evidence which suggests that different strategies are
associated with varying degrees of cancer risk-reduction,
such evidence is nevertheless derived from retrospective
and short follow-up prospective studies in addition to
hypothetical mathematical models. It is known that ret-
rospective studies do not provide the highest level of
evidence compared with randomised controlled studies;
they are often less robust and usually carry a degree of
bias. Furthermore, they tend not to be standardised in
relation to confounding factors, such as patients’ age,
socio-economic class, and other factors.
Currently, there are no randomised controlled trials
concerned with the demonstration of the potential bene-
fits or harms of prophylactic surgery. This is due to dif-
ferent factors, such as the small number of BRCA
mutation carriers, which necessitate multiple centres to
participate. Conducting a randomised controlled trial in
multiple centres poses potential problems, namely a lack
of standardisation, which is the main issue as different
surgeons have different surgical risk-reducing techni-
ques. Furthermore, in light of the currently available evi-
dence from retrospective studies, randomisation is
deemed unethical, and women may therefore opt for
risk-reducing surgery rather than observation.
Conclusions
Selecting the most appropriate risk-reducing strategy is
not a straightforward task. The impact of risk-reducing
strategies on cancer risk, survival, and overall quality of
life are the key criteria considered for making a good
decision. There is no sole risk-reducing strategy which
is able to fully meet all expectations and requirements
in an individual woman. On the one hand, non-surgical
procedures provide a good body image and quality of
life, but may be associated with increased risk of
advanced-stage cancer and mortality; on the other hand,
surgery ensures a very high protection from cancer but
is associated with a number of disadvantages of invasive-
ness, non-reversibility and surgical morbidity.
Based on the available literature, it is deemed appro-
priate to acknowledge that the clinical management of
cancer risk in BRCA1 and BRCA2 mutation carriers is a
rather complex and stressful task, which should consider
Salhab et al. BMC Women?’?s Health 2010, 10:28
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preferences can be informed by accurate knowledge of
the risks and benefits of the interventions considered.
Available studies confirm the essential role of PBSO in
reducing the risk of both breast and ovarian cancer.
Furthermore, other options for risk reduction should be
considered, such as chemoprevention and risk-reducing
mastectomy [74]. Although coordinated, PBM and
PBSO are feasible procedures with acceptable morbidity
in selected high-risk patients [97]; the timing of prophy-
lactic surgery is still a matter of paramount importance
to both patients and clinicians to consider during the
counselling process.
It is recommended that prophylactic surgery should be
performed as soon as possible, simply because of the
early development of cancer in BRCA mutation carriers.
Although ovarian cancer rarely occurs in premenopausal
w o m e n ,i ti sa d v i s e dt h a tB R C Am u t a t i o nc a r r i e r s
should undergo PBSO immediately after childbearing is
complete in order to reduce the risk of early breast can-
cer development.
Prospective randomised controlled trials examining
the various interventions in relation to the woman’sa g e
and type of mutation are needed. However, the rando-
misation of BRCA carriers to different arms of trials is
an extremely difficult and rather impossible process
given the current available evidence.
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